| Date Filed | Type | Description |
| 08/11/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/15/2023 |
SC 13D
| CLS Therapeutics, LLC reports a 9.7% stake in Xenetic Biosciences, Inc. |
| 06/02/2023 |
8-K
| Other Events Interactive Data |
| 05/12/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/23/2023 |
8-K
| Quarterly results |
| 03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 12/22/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 12/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/09/2022 |
4
| Kornberg Roger D. (Director) has filed a Form 4 on Xenetic Biosciences, Inc.|
Txns:
| Granted 25,000 options
@ $0.4367, valued at
$10.9k
|
|
| 12/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/09/2022 |
8-K
| Quarterly results |
| 12/02/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/21/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/17/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/17/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/13/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 10/12/2022 |
8-K
| Unregistered Sales of Equity Securities Interactive Data |
| 10/03/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 08/12/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/07/2022 |
8-K
| Quarterly results |
| 06/06/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/04/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 04/28/2022 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
|